Eugene

[email protected]

LATEST

Merck and Co. To Acquire Peleton Therapeutics in $2.2-Billion Deal
By

By
Merck & Co. has entered into a definitive agreement with Peleton Therapeutics, a clinical-stage biopharmaceutical company, under which Merck, through a subsidiary, will acquire all outstanding shares of Peleton for…

Thermo Fisher Scientific To Invest $50 Million in Bioproduction Expansion
By

By
Thermo Fisher Scientific has announced a $50-million investment in its global bioproduction capabilities to expand capacity for manufacturing single-use bioprocess container (BPC) systems at its site in Cramlington, United Kingdom…

Genentech, Parvus In $800-Million-Plus Licensing Deal For Autoimmune Drugs
By

By
Roche’s Genentech has entered into a global collaboration and licensing agreement with Parvus Therapeutics, a privately held biopharmaceutical company, to develop, manufacture and commercialize Navacim therapeutics for treating autoimmune disorders,…

WuXi Biologics To Build Vaccine Mfg Plant; Plans $3-Billion Supply Pact
By

By
WuXi Biologics, a contract biologics manufacturer, has signed a letter of intent for a strategic partnership with an unnamed vaccine maker for a 20-year supply contract, estimated to be worth…

Catalent Completes $1.2-Billion Acquisition of Paragon Bioservices
By

By
Catalent has completed its $1.2-billion acquisition of Paragon Bioservices, a contract provider of viral vector development and manufacturing services for gene therapies. Paragon has development and manufacturing capabilities in adeno-associated…

Xellia To Divest North Carolina Mfg Plant to Sagent
By

By
Xellia Pharmaceuticals, a specialty pharmaceutical company focused on anti-infective treatments and globally headquartered in Copehangen, Denmark, has entered into an agreement to divest its Raleigh, North Carolina manufacturing plant to…

Glenmark Appoints CEO of New Innovation Company
By

By
Glenmark Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, has appointed Alessandro Riva, MD, as Chief Executive Officer of its new innovation company. Dr. Riva is currently Executive Vice President, Oncology Therapeutics…

FDA Continues Investigation and Recalls for Generic Sartan Drugs
By

By
The US Food and Drug Administration (FDA) is updating the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic “sartan”-containing products, angiotensin II receptor blockers (ARBs), used to…

Endo Terminates $190-Million Acquisition Agreement With Somerset
By

By
Endo International, a generics and specialty branded pharmaceutical company, has announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc. and Par Formulations Private Limited, have terminated their respective agreements…

Novartis, Blackstone Invest $250 Million to Launch Anthos Therapeutics
By

By
Novartis and Blackstone Life Sciences, a private investment firm, have launched Anthos Therapeutics, a new biopharmaceutical company focused on advancing targeted therapies for high-risk cardiovascular patients. The company will be…